FORM 8.3

FORM 8.3

FORM 8.3

FORM 8.3

FORM 8.3

MONACO, April 02, 2025 (GLOBE NEWSWIRE) -- Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625% Series B Cumulative Redeemable Perpetual Preferred Stock (the “Series B Preferred Stock”) (NYSE: CMRE PR B), US $0.531250 per share on its 8.50% Series C Cumulative Redeemable Perpetual Preferred Stock (the “Series C Preferred Stock”) (NYSE: CMRE PR C) and US $0.546875 per share on its 8.75% Series D Cumulative Redeemable Perpetual Preferred Stock (the “Series D Preferred Stock”) (NYSE: CMRE PR D). The dividend for the Series B Preferred Stock, the Series C Preferred Stock and the Series D Preferred Stock is for the period from January 15, 2025 to April 14, 2025. The dividend will be paid on April 15, 2025 to all holders of record as of April 14, 2025 of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock.

Ap27

TORONTO, April 02, 2025 (GLOBE NEWSWIRE) -- AGF Investments Inc. (AGF Investments) today announced additional ad hoc distributions for AGF Systematic Global Multi-Sector Bond ETF (ticker: QGB), AGF Systematic International Equity ETF (ticker: QIE) and AGF Systematic US Equity ETF (ticker: QUS), which usually pay quarterly/annual distributions.

TORONTO, 02 avr. 2025 (GLOBE NEWSWIRE) -- Placements AGF Inc. (« Placements AGF ») a annoncé aujourd’hui des distributions supplémentaires particulières pour le FNB Obligations mondiales Multisecteurs – Approche systématique AGF (symbole : QGB), le FNB Actions internationales – Approche systématique AGF (symbole : QIE) et le FNB Actions américaines – Approche systématique AGF (symbole : QUS), qui versent habituellement des distributions trimestrielles ou annuelles.

SFL Corporation Ltd. (NYSE: SFL) (“SFL” or the “Company”) advises that the 2025 Annual General Meeting of the Company will be held on May 8, 2025. The record date for voting at the Annual General Meeting is set to April 4, 2025. A copy of the Notice of Annual General Meeting and associated information, including the Company’s Annual Report on Form 20-F, will be distributed and made available on the Company’s website at www.sflcorp.com prior to the meeting.

To Nasdaq Copenhagen

FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company’s common stock with an exercise price of $12.49, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on April 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on April 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

Acquisition Paves the Way for Agentic Education, Delivering Personalized Learning at Scale

Expands Soul & Science Across North America

CRN’s annual list spotlights vendors leading IoT Innovation

- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - 
- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) -

The strategic acquisition consolidates Nayax’s Distribution Channels and Expands Market Reach in the Benelux

Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer’s disease recently published in The Journal of Prevention of Alzheimer's Disease